Xilio Therapeutics, Inc. (XLO) stock
Close on Nov 12, 2026Market cap $47.65MP/E –Yield –
Xilio Therapeutics, Inc. grew revenue 73.0% to $55.01M over the twelve months to Sep 30, 2026. Free cash flow was -$57.63M. At the latest close the market valued the company at $47.65M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $47.65M
- P/E ratio
- –
- Price to sales
- 0.87
- Price to book
- 0.70
- Dividend yield
- –
- Free cash flow yield
- -120.94%
Fundamentals
- Revenue
- $55.01M
- Net income
- -$11.49M
- EPS, diluted
- -$4.19
- Free cash flow
- -$57.63M
- Book value per share
- $3.47
- Diluted shares
- 20M
Trading
- Next earnings
- Mar 22, 2027 (estimated, before the open)
- Previous close
- $8.47
- Open
- $8.25
- Day's range
- $7.96 – $8.25
- Volume
- 9,085
- Average volume (20 days)
- 15,735
- Beta (5 years)
- 0.90
- 52-week range
- $6.47 – $11.30
- RSI (14 days)
- 45.7
- Volatility (1 year)
- 46.0%
- Relative volume
- 0.49×
- WACC
- 9.4%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | XLO | S&P 500 | Difference | XLO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.2% | -2.7% | −6.5 pts | ||
| 3 months | -9.0% | -1.7% | −7.2 pts | ||
| Year to date | -8.1% | +11.9% | −20.0 pts | ||
| 1 year | -23.9% | +12.0% | −35.9 pts | ||
| 3 years | -58.8% | +78.2% | −137.0 pts | -25.6% | +21.2% |
| 5 years | -97.3% | +73.2% | −170.6 pts | -51.6% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Xilio Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Unlocking the Potential of Immuno-Oncology Therapies March 9, 2026 © 2026 Xilio Therapeutics, Inc. ®Update
- Update
About Xilio Therapeutics
Pharmaceutical Preparations
Xilio Therapeutics is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer treatment. Using proprietary protein engineering and masking technology, the company designs biologic therapies, including masked multi-specific molecules, engineered to activate selectively within the tumor microenvironment through tumor-specific proteases. These therapies aim to deliver localized therapeutic activity while minimizing the toxicities commonly caused by systemic exposure. The company develops programs for individuals living with cancer and engages in strategic collaboration and licensing agreements with biopharmaceutical partners, including Gilead Sciences and AbbVie.
Company profile, executives and historyXilio Therapeutics stock: common questions
What is Xilio Therapeutics's stock price?
XLO closed at $8.24 on Nov 12, 2026, down 2.72% on the day. Over the past 52 weeks it traded between $6.47 and $11.30.
What is Xilio Therapeutics's market cap?
Xilio Therapeutics was worth $47.65M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is XLO's P/E ratio?
Xilio Therapeutics lost money over fiscal 2025 (diluted EPS -$4.19), so it has no meaningful P/E ratio.
How much revenue does Xilio Therapeutics make?
Xilio Therapeutics reported revenue of $55.01M for the twelve months to Sep 30, 2026, up 73.0% from a year earlier.
Does Xilio Therapeutics pay a dividend?
No. Xilio Therapeutics has not paid a cash dividend over the last twelve months.
When does Xilio Therapeutics report earnings next?
Xilio Therapeutics is expected to report Q4 FY2026 results on Mar 22, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has XLO stock performed over the past year?
Including dividends, XLO returned -23.9% over the past year, against +12.0% for the S&P 500.
Who are Xilio Therapeutics's competitors?
Companies most similar to Xilio Therapeutics by business, industry and size include TNGX, NKTR, PRLD, ENTA, XNCR.
See a number that looks wrong?